CRON 8-K SEC Filing Analysis

Latest settled — T+5d

CRON ▼ -4.73% at T+5d

LONG call ✗ call lost -4.73% · α vs SPY -4.64% · entry $2.75 → $2.62

Next anchor: T+20d in 19d

Currently $2.71 · -1.27% from $2.75 entry

Entry anchored
May 8, 03:59 PM ET
via Databento tick

T+1d

+0.73%

call +0.73% · α +0.86%

$2.77

settled 9d ago

T+5d

-4.73%

call -4.73% · α -4.64%

$2.62

settled 3d ago

T+20d

—

call — · α —

—

in 19d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

Cronos Group reported strong Q1 2026 results with net revenue up 40% YoY to $45.2M and net income more than doubling to $15.7M, driven by record cannabis flower sales in Israel and international markets. The company also extended the closing date for its CanAdelaar acquisition to September 9, 2026, and announced a new $50M share repurchase program. The combination of accelerating revenue growth, expanding profitability, and a $822M cash-rich balance sheet supports a bullish outlook.

Key Financial Metrics

Free Cash Flow

$9.1M

Gross Margin

42%

Deal Value

$67.0M

Actionable Insight

Strong Q1 results with accelerating revenue growth and profitability, plus a $822M cash position, make CRON a standout in the cannabis sector. Monitor the CanAdelaar closing timeline (now Sept 9) as a catalyst for European expansion. The $50M buyback provides downside support. Consider adding on any regulatory delay pullback.

Key Facts

Q1 2026 net revenue of $45.2M, up 40% YoY from $32.3M
Net income of $15.7M, up 103% YoY from $7.7M
Adjusted EBITDA of $5.1M, up 122% YoY from $2.3M
Israel net revenue grew 53% YoY; international markets outside Israel grew 97% YoY
Cash and cash equivalents of $821.9M as of March 31, 2026
CanAdelaar acquisition long-stop date extended to September 9, 2026
New $50M share repurchase program authorized, succeeding prior program
Repurchased 13.4M shares for ~$33.5M under prior program

Financial Impact

Revenue growth of 40% YoY to $45.2M, net income doubled to $15.7M, Adjusted EBITDA up 122% to $5.1M

revenuenet incomeadjusted EBITDAcash

Risk Factors

CanAdelaar acquisition may face further regulatory delays or fail to close
Anti-dumping investigation in Israel could disrupt key market
Middle East conflict could impact Israel operations
Operating expenses rising 18% YoY may pressure margins if revenue growth slows

Market Snapshot

Exchange

Nasdaq

Sector

Medicinal Chemicals & Botanical Products

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001656472-26-000032
Exhibit: exhibit-canadelaarspaamend.htm	0001656472-26-000032
Document: cron-20260508.htm	0001656472-26-000032
Document: 0001656472-26-000032-index-headers.html	0001656472-26-000032
Document: 0001656472-26-000032-index.html	0001656472-26-000032
Document: 0001656472-26-000032.txt	0001656472-26-000032
8-K Data (Synthetic)	0001656472-26-000032

3 reports for CRON

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CRON — sortable, filterable
	Type				Now
May 11, 2026 10d ago	8-K BULLISH ★ 7/10	$2.75 $2.62	▼ −4.73%	▼ −4.64%	$2.71 (−1.27%)
Apr 20, 2026 4w ago	Press Release BEARISH ★ 6/10	$2.76 $2.70	▲ +2.17%	▲ +3.09%	$2.71 (+1.63%)
Feb 26, 2026 12w ago	8-K BULLISH ★ 8/10	$2.67 $2.57	▼ −3.75%	▼ −2.62%	$2.71 (+1.69%)

US Market Status

Market Open — Closes in 3h 53m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access